Figure 6. Combinatorial action of IACS‐010759 and ascorbate against Myc‐overexpressing lymphoma xenografts.

The indicated lymphoma cell lines and PDX samples were xenografted in recipient animals and tumors allowed to develop to detectable sizes prior to randomization and treatment with IACS‐010759 (IACS) by oral gavage and/or ascorbate (Asc) by intraperitoneal injection, as indicated (see Materials and Methods). Daily doses and the number of animals per group (n) are indicated in parenthesis.

• A, B
  Tumor progression (mm³) in CD1 nude mice bearing subcutaneous Ramos (A) or DoHH2 tumors (B).
• C, D
  Tumor progression in NSG mice injected with the luciferase‐positive DHL‐derived PDX lines DFBL‐20954 (C) or DFBL‐69487 (D), as determined by in vivo imaging and quantification of bilateral femur radiance efficiency. Examples from the control and double‐treated groups are shown at the bottom.

Data information: In each panel, the plot on the right shows the data for individual groups on the indicated day. Error bars: SD; n = animals per group. Right: one‐way between‐group ANOVA. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

Source data are available online for this figure.